ReviewBiopolymers2012
Protease-resistant peptide design-empowering nature's fragile warriors against HIV.
Review in Biopolymers, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- The role of secondary structures of peptide polymers on antimicrobial efficacy and antibiotic potentiation.bioRxiv : the preprint server for biology · 2024Article
- Systemic Dendrimer-Peptide Therapies for Wet Age-Related Macular Degeneration.Pharmaceutics · 2023Article
- Efficient Synergistic Antibacterial Activity of α-MSH Using Chitosan-Based Versatile Nanoconjugates.ACS omega · 2023Article
- Short hydrocarbon stapled ApoC2-mimetic peptides activate lipoprotein lipase and lower plasma triglycerides in mice.Frontiers in cardiovascular medicine · 2023Article
- Synthesis and Studies of Bulky Cycloalkyl α,β-Dehydroamino Acids that Enhance Proteolytic Stability.Organic letters · 2022Article
- Stimuli Induced Uptake of Protein-Like Peptide Brush Polymers.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Peptide-Conjugated Nano Delivery Systems for Therapy and Diagnosis of Cancer.Pharmaceutics · 2021Review
- Rational design of thioamide peptides as selective inhibitors of cysteine protease cathepsin L.Chemical science · 2021Article
- Estimating peptide half-life in serum from tunable, sequence-related physicochemical properties.Clinical and translational science · 2021Article
- Towards a streamlined synthesis of peptides containing α,β-dehydroamino acids.Tetrahedron letters · 2021Article
- Molecular engineering of antimicrobial peptides: microbial targets, peptide motifs and translation opportunities.Biophysical reviews · 2021Review
- d-Retro Inverso Amylin and the Stability of Amylin Fibrils.Journal of chemical theory and computation · 2020Article
- New Morphiceptin Peptidomimetic Incorporating (1Molecules (Basel, Switzerland) · 2020Article
- Impact of Dehydroamino Acids on the Structure and Stability of Incipient 3The Journal of organic chemistry · 2020Article
- Targeting Ligands Deliver Model Drug Cargo into the Central Nervous System along Autonomic Neurons.ACS nano · 2019Article
- Characterization of resistance to a potent D-peptide HIV entry inhibitor.Retrovirology · 2019Article
- Next Generation Techniques for Determination of Protein-Protein Interactions: Beyond the Crystal Structure.Current pathobiology reports · 2019Article
- A Comprehensive Review on Current Advances in Peptide Drug Development and Design.International journal of molecular sciences · 2019Review
- Review
- Peptide-nanoparticle conjugates: a next generation of diagnostic and therapeutic platforms?Nano convergence · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Peptides have great potential as therapeutic agents, but their use is often limited by susceptibility to proteolysis and their resulting in vivo fragility. In this review, we focus on peptidomimetic approaches to produce protease-resistant peptides with the potential for greatly improved clinical utility. We focus on the use of mirror-image (D-peptide) and ß-peptides as two leading approaches with distinct design principles and challenges. Application to the important and difficult problem of inhibiting HIV entry illustrates the current state-of-the-art in peptidomimetic technologies. We also summarize future directions for this field and highlight remaining obstacles to widespread use of protease-resistant peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.